Sponsor of the Day:
Jerkmate
https://www.statnews.com/2026/04/13/biotech-news-gsk-advacing-ovarian-cancer-drug-mo-rez/
Revolution Medicines, GSK, Allogene: Readout Newsletter
Apr 13, 2026 - Today's biotech news includes Revolution Medicines 'unprecedented' cancer trial data, Allogene's off-the-shelf CAR-T, and more
revolution medicinesreadout newslettergskallogene
https://allogene.com/privacy-notice/
Privacy Notice - Allogene
Apr 16, 2026 - PRIVACY NOTICE Effective July 2025 PRIVACY NOTICE Allogene Therapeutics (“Allogene”, “we”, “us” and/or “our”) respects your privacy and we want you to be...
privacy noticeallogene
https://allogene.com/terms-of-use/
Terms of Use - Allogene
Apr 16, 2026 - TERMS OF USE EFFECTIVE APRIL 2026 LEGAL DISCLAIMERS This web site, and the documents contained in (or directly accessible from) this web site, include...
termsuseallogene
https://allogene.com/alpha3/
ALPHA3 - Allogene
Mar 13, 2026 - ALPHA3 NOW ENROLLING The ALPHA3 trial aims to embed an investigational allogeneic CAR T product as part of the first‑line (1L) treatment regimen in LBCL...
alpha3allogene
https://allogene.com/about-us/
About Us - Allogene
Apr 16, 2026 - REDEFINING THEFUTURE OF CAR T LEARN ABOUT OUR SCIENCE Allogene Therapeutics is a clinical-stage biotechnology company with a single-minded focus on pioneering...
usallogene
https://www.hematon.nl/ziektebeelden/stamceltransplantatie/allogene-stamceltransplantatie
Allogene stamceltransplantatie | Patiëntenorganisatie Hematon
Bij allogene stamceltransplantatie krijg je stamcellen van een donor. Lees hier over de behandeling, de kansen en de risico's en wat u zelf kunt doen.
allogenehematon
https://www.biopharmadive.com/news/allogene-cema-cel-allogeneic-lymphoma-data/817316/
Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphoma | BioPharma Dive
Initial results from a high-stakes trial indicate the biotech may have finally found a niche in lymphoma care for a donor-derived cell therapy.
data suggestcould delaybiopharma diveallogenecar
https://www.statnews.com/2026/03/26/allogene-car-t-lymphoma-treatment-study/
Allogene's off-the-shelf CAR-T is nearing an early but pivotal study readout
In this week's edition of
allogeneshelfcarnearingearly